• BSTE Stock Makes "Healthy" Run With Leaders Tuesday, 27 Mar 2007 | 9:52 AM ET

    Hey folks. Here's the best performing trades by % gain from Friday's close to Monday's close: Biosite--If you bought on Friday at $55.38 and held/sold on Monday with a close of $83.80, the contestant gained 51.32% on the trade (9 out of the 10 current weekly leaders as of Monday's close bought BSTE on Friday).

  • French drug maker Sanofi Aventis’ board is split over whether to acquire U.S. pharmaceutical company Bristol-Myers Squibb in a deal that could be worth $54 billion, London newspaper The Times reported.

  • Poor Management + Activist = $$$ Monday, 26 Mar 2007 | 6:51 PM ET

    Take a company that’s being managed into the ground, add an activist investor to stir things up, and you’ve got a stock that should go higher. Tonight, Cramer’s got a play that fits the model.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • More than half a million people a year with chest pain are getting an unnecessary or premature procedure to unclog their arteries because drugs are just as effective, suggests a landmark study that challenges one of the most common practices in heart care.

  • Merck, Schering To Develop Combo Pill With Lipitor Monday, 26 Mar 2007 | 12:32 PM ET

    Merck and Schering-Plough said on Monday they were beginning development of a cholesterol-lowering product that would combine their Zetia drug with Pfizer's Lipitor.

  • Abandoned Pfizer Drug Fails To Slow Artery Clogging Monday, 26 Mar 2007 | 11:11 AM ET

    Pfizer's abandoned experimental drug torcetrapib failed to slow clogging of heart arteries even as it boosted "good" cholesterol levels, according to a study presented Monday.

  • Beckman Coulter to Buy Biosite for $1.55 Billion Monday, 26 Mar 2007 | 9:37 AM ET

    Beckman Coulter, which makes products for biomedical tests, said on Sunday it would acquire Biosite for about $1.55 billion to expand its presence in the market for diagnosis and assessment of heart failure.

  • AstraZeneca's Crestor cholesterol drug slowed thickening in the neck arteries of people at low risk for heart attacks and strokes, but it failed to reverse thickening as researchers had hoped it would.

  • The Geek Squad Friday, 23 Mar 2007 | 5:28 PM ET

    When Rodman and Renshaw biotech analyst Mike King told me "Genentech was gonna get its geek on," at its annual analyst meeting today I didn't realize how spot on he might be. Today the company took a deep dive into the science of its drug research and development pipeline...cabbage looper worms and all. I'm not kidding. But the ultimate geek factor came from the company's Chairman and CEO Art Levinson.

  • Amgen's stock fell sharply after the company said it had discontinued a key clinical trial of its drug Vectibix in combination with other drugs as an initial treatment for colon cancer. The report helped boost shares of other drugmakers such as ImClone Systems, which makes a competing drug Erbitux.

  • Here some of Friday's big movers on European stock markets

  • CNBC's Domm: Today's Agenda in the Markets Friday, 23 Mar 2007 | 8:58 AM ET

    Stocks are edging higher ahead of the opening. Existing home sales data at 10 am New York time could influence direction but for now investors face a flurry of Friday morning corporate news headlines.

  • Dendreon Going to the Big Dance Thursday, 22 Mar 2007 | 3:42 PM ET

    A biotech story that I've been following since I started on this beat around four or five years ago is about to go through what's referred to in the biotech world as a major "binary event". In other words, if things go well, the stock could skyrocket. If things go badly, then the stock could tank.

  • Stats, Stats And More Stats  For You Wednesday, 21 Mar 2007 | 10:45 AM ET

    We've got some of the latest contest statistics on most active, widely held, etc.  So, without any further introduction, here they are. The numbers are as of Tuesday, March 20, 2007.

  • Pfizer Prevails in Patent Suit Against Teva Tuesday, 20 Mar 2007 | 3:55 PM ET

    The decision bars Teva from launching a competitor drug in the U.S. until December 2015, Pfizer said.

  • The grant, for Cleveland BioLabs' Protectan CBLB502, is designed to fund "development leading to the acquisition" of an radiation countermeasure.

  • Ranbaxy Out of Merck KGaA Generic Hunt; Torrent In? Tuesday, 20 Mar 2007 | 3:29 AM ET

    Ranbaxy Laboratories is no longer in the running to buy the generic drug business of Germany's Merck, India's CNBC TV18 reported Tuesday. Ranbaxy withdrew from the second round of bidding for the business, the television station said.

  • The ACC & DNA; Big Apple to the Big Easy Monday, 19 Mar 2007 | 2:24 PM ET

    We're gearing up for a busy few days on the beat starting Friday. That's when biotech giant Genentech holds its annual analyst meeting in New York City. We'll be there. Last year the company put out new, boosted financial guidance in the middle of the trading day and it moved the stock. CEO Art Levinson told the crowd of analysts he liked to time it that way so they'll stick around for the whole day.

  • Cepheid Meningitis Drug Gets Approval from FDA Friday, 16 Mar 2007 | 1:14 PM ET

    The test, called the Xpert EV test, can detect the condition in 2.5 hours compared with other products that can take as long as a week, the FDA said.

  • U.S. drug maker Bristol-Myers Squibb is moving assets of up to $25 billion from an Irish holding company, it said on Friday, fanning worries in Ireland that it is growing less competitive.